Scottsdale Scientific Enters the Multi-Billion Dollar Cold Relief Market by Signing an Exclusive Distribution Agreement for Oralmat.SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nov. 12, 1998--Scottsdale Scientific Inc. (Symbol: STDS STDS System Transition and Deployment Strategy STDS Submarine Tactical Display System STDS Systems Technology Departmental Services STDS Studio Set ), through it's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , NutriCology Inc., announced an exclusive contract with Schumacher Pharmaceuticals Pty. Ltd. of Australia, to distribute the Oralmat(TM) line of products in the United States. Oralmat(TM) solution is a non-toxic rye extract developed in Australia and is currently being marketed for the temporary relief of cold, cough, flu, sore throat and asthmatic related symptoms in Australia. Oralmat(TM) products are natural immunomodulators and are easily administrated. Preliminary positive results have already been reported from an ongoing clinical asthma trial of Oralmat's(TM) herbal extract at The John Hunter Hospital The John Hunter Hospital (sometimes known as the JHH or more colloquially the John) is the principal referral centre and a community hospital for Newcastle, Lake Macquarie and Northern New South Wales. It is the main teaching hospital of the University of Newcastle. in New Castle, Australia; under the direction of Dr. David Cooper (pediatrics) and Dr. John Falconer of Reproductive Medicine. Dr. Falconer stated, "The importance of this trial should not be underestimated because the symptoms of other wide range serious illnesses will be monitored, during these trials." Marianne Sum, president of Scottsdale Scientific stated, "This agreement with Schumacher Pharmaceuticals diversifies our existing product line and offers our customers advanced alternatives for flu type and asthmatic related symptoms." Scottsdale Scientific Inc., through it's wholly owned subsidiary, NutriCology Inc. is an innovative leader in nutraceutical research and product formulation. Since 1979, the company is noted for quality, hypoallergenic hy·po·al·ler·gen·ic adj. Having a decreased tendency to provoke an allergic reaction. hypoallergenic (hī´pōal´urjen´ik), adj nutritional supplements and in 1997 supplied products to approximately 5,000 physicians and health care practitioners. NutriCology was the first in the U.S. to introduce numerous specialty products including melatonin melatonin: see pineal gland. melatonin Hormone secreted by the pineal gland of most vertebrates. It appears to be important in regulating sleeping cycles; more is produced at night, and test subjects injected with it become sleepy. , a neurohormone neurohormone /neu·ro·hor·mone/ (noor´o-hor?mon) a hormone secreted by a specialized neuron into the bloodstream, the cerebrospinal fluid, or the intercellular spaces of the nervous system. , germanium germanium (jərmā`nēəm) [from Germany], semimetallic chemical element; symbol Ge; at. no. 32; at. wt. 72.59; m.p. 937.4°C;; b.p. 2,830°C;; sp. gr. 5.323 at 25°C;; valence +2 or +4. sesquioxide Ses`qui`ox´ide n. 1. (Chem.) An oxide containing three atoms of oxygen with two atoms (or radicals) of some other substance; thus, alumina, For additional information, visit our web-site at www.nutricology.com Disclaimer: This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion